Skip to main content

Table 2 Disease progression

From: Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS® trials

N (%)

Anti-acid medication at baseline

No anti-acid medication at baseline

Nintedanib (n = 244)

Placebo (n = 162)

Nintedanib (n = 394)

Placebo (n = 261)

Absolute decline in FVC ≥10% predicted or death

77 (31.6)

77 (47.5)

96 (24.4)

98 (37.5)

Criterion reached first

 Absolute decline in FVC ≥10% predicted

67 (27.5)

65 (40.1)

81 (20.6)

88 (33.7)

 Death

10 (4.1)

12 (7.4)

15 (3.8)

10 (3.8)

Absolute decline in FVC ≥5% predicted or death

135 (55.3)

122 (75.3)

195 (49.5)

181 (69.3)

Criterion reached first

 Absolute decline in FVC ≥5% predicted

129 (52.9)

117 (72.2)

188 (47.7)

175 (67.0)

 Death

6 (2.5)

5 (3.1)

7 (1.8)

6 (2.3)